KPV

🔬Kas yra KPV

KPV is a naturally occurring C-terminal tripeptide (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (α-MSH). Despite its small size, KPV retains the potent anti-inflammatory properties of the parent hormone without its melanogenic effects. It exerts its action primarily through inhibition of NF-κB nuclear translocation, a master regulator of inflammatory gene expression, effectively reducing pro-inflammatory cytokine production including TNF-α, IL-6, and IL-1β. Research has demonstrated its therapeutic potential in models of inflammatory bowel disease, dermatitis, and wound healing, where it promotes resolution of inflammation while supporting tissue repair processes.

📊Klinikiniai tyrimai ir rezultatai

KPV is a C-terminal tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH), retaining the parent molecule's potent anti-inflammatory properties:

• ▪Demonstrated significant anti-inflammatory effects in DSS-induced colitis models, reducing disease activity index scores and histological damage (Kannengiesser et al., Inflamm Bowel Dis, 2008; PMID: 18092346)
• ▪Transported via PepT1 into colonocytes where it inhibited NF-κB activation and reduced pro-inflammatory cytokine production (Dalmasso et al., J Biol Chem, 2008; PMID: 18541529)
• ▪Nanoparticle-loaded KPV formulations showed enhanced colonic delivery and superior anti-inflammatory efficacy compared to free KPV in IBD models
• ▪Suppressed TNF-α, IL-6, and IL-1β expression in LPS-stimulated macrophages through melanocortin receptor-independent pathways
• ▪Accelerated mucosal healing and restored epithelial barrier integrity in chronic intestinal inflammation models
• ▪Inhibited activation of the NLRP3 inflammasome, a key driver of chronic inflammatory diseases

KPV demonstrates potent, targeted anti-inflammatory activity with a particularly strong tropism for intestinal tissue, making it one of the most promising peptides for inflammatory bowel disease research.

🏆Privalumai

• Potent Anti-Inflammatory – Inhibits NF-κB and suppresses TNF-α, IL-6, IL-1β production
• Targeted Gut Healing – Transported directly into colonocytes via PepT1 for localized action
• Restores Epithelial Barrier – Repairs intestinal lining integrity in chronic inflammation
• NLRP3 Inflammasome Inhibition – Blocks a key inflammatory cascade implicated in multiple diseases
• Mucosal Healing Acceleration – Promotes faster recovery of damaged intestinal mucosa
• Well-Tolerated – Minimal systemic effects due to targeted intestinal delivery mechanism

⚠️Galimas šalutinis poveikis

• ▪Very well tolerated with minimal documented adverse effects
• ▪Rare mild injection site reactions

🎯Idealiai tinka

• →Inflammatory bowel disease (IBD) and colitis research
• →Gut barrier integrity restoration and leaky gut protocols
• →Chronic systemic inflammation management
• →Autoimmune condition research involving intestinal inflammation
• →Combining with BPC-157 for comprehensive GI tract healing
• →Skin inflammation and dermatological condition research